NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a note issued to investors on Saturday. The firm set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets cut their target price on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research note on Monday, November 11th.

NovaBay Pharmaceuticals Stock Down 1.2 %

NovaBay Pharmaceuticals stock opened at $0.62 on Friday. The business has a 50 day moving average price of $0.63 and a two-hundred day moving average price of $0.90. NovaBay Pharmaceuticals has a 12 month low of $0.36 and a 12 month high of $9.08. The stock has a market cap of $3.03 million, a price-to-earnings ratio of -0.01 and a beta of 0.65.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.